Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis despite advancements in treatment and diagnosis. Tumor recurrence, developing in most patients (>90%), poses a major challenge due to tumor heterogeneity and limited understanding of post-treatment evolution. Previous studies have...
COVID-19 is an emerging, rapidly evolving siituation.
What people with cancer should know: https://www.cancer.gov/coronavirus
Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers
Get the latest public health information from CDC: https://www.coronavirus.gov
Get the latest research information from NIH: https://www.nih.gov/coronavirus
News and Announcements
All | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010
Displaying 1 - 20 of 264March 29, 2024
The Clinical Proteomic Tumor Analysis Consortium (CPTAC) recently held its Scientific Investigator Meeting in Portland, Oregon at the Oregon Health & Science University campus. The meeting featured key scientific and programmatic updates spanning multiple cancer types presented by consortium...
March 20, 2024
The following is the third entry in a new Q&A series highlighting selected Clinical Proteomic Tumor Analysis Consortium (CPTAC) researchers and their work. Join us as we discuss multiple facets of proteomics research with Nicole Tignor, PhD, Assistant Professor at the Icahn School of Medicine at...
February 23, 2024
Small cell lung cancer (SCLC) is an aggressive form of lung malignancy with historically poor prognoses and limited options for targeted treatment. The low availability of suitable biospecimens has also hampered large molecular characterization efforts.
February 14, 2024
The tumor microenvironment (TME) is a complex network which plays a crucial role in cancer progression and treatment responses. In a recently published Pan Cancer analysis, the Clinical Proteomic Tumor Analysis...
January 22, 2024
Acute Myeloid Leukemia (AML) is a hematologic malignancy characterized by the rapid proliferation of abnormal myeloid cells in the bone marrow and blood. AML is known for its heterogeneity, presenting challenges in treatment and predicting patient outcomes.
January 8, 2024
The following is the second entry in a new Q&A series highlighting selected Clinical Proteomic Tumor Analysis Consortium (CPTAC) researchers and their work. Join us as we discuss multiple facets of proteomics research with Jeffrey Whitaker, PhD, Director of Proteomics within the Paulovich Lab at...
December 5, 2023
A new collaboration between the Morehouse School of Medicine (MSM) and the Clinical Proteomic Tumor Analysis Consortium (CPTAC) aims to enhance diversity of cancer patients included in proteogenomic studies.
November 27, 2023
The following is the first entry in a new Q&A series highlighting selected Clinical Proteomic Tumor Analysis Consortium (CPTAC) researchers and their work. Join us as we discuss molecular and computational techniques in biology with Natalie Clark, PhD from the Proteomics Platform at the Broad...
October 30, 2023
The National Cancer Institute (NCI) and Lund University in Sweden are pleased to announce the signing of an extension to their memorandum of understanding (MOU) for proteogenomics cancer research. The MOU, involving NCI’s International Cancer Proteogenome Consortium (ICPC) and Clinical Proteomic...
October 17, 2023
Intrahepatic cholangiocarcinomas (iCC) pose a diagnostic and treatment challenge due to their rarity and inter/intrapatient heterogeny.
September 20, 2023
Proteogenomic characterization of patient tissues has enriched our understanding of liver cancer, uncovering potential therapeutic targets, new subtypes, and offering hope for more effective treatments. However, there remains a gap in translating these findings into clinical practice.
September 7, 2023
The Cancer Imaging Archive (TCIA), managed by the National Cancer Institute's Cancer Imaging Program (CIP), collects, curates, and hosts digital histopathology and standard-of-care radiology imaging from CPTAC-enrolled patients to provide data for imaging-omics research. Algorithmic analysis of...
August 23, 2023
Recent strides in the field of genomics, exemplified by initiatives like The Cancer Genome Atlas (TCGA), have illuminated the genetic landscape of endometrial carcinoma (EC). The identification of four distinct EC...
August 14, 2023
Researchers from the National Cancer Institute’s (NCI) Clinical Proteomic Tumor Analysis Consortium (CPTAC) have produced a resource of global proteomic and post-translational modifications, whole genome and whole exome sequencing, miRNA and totalRNA sequencing, DNA methylation, imaging, and clinical...
August 4, 2023
In an effort recently published in Cell, CPTAC researchers aimed to identify patients with high-grade serous ovarian cancer (HGSOC) who may not respond to standard therapies. At present, there is no way...
July 19, 2023
Recently published in Nature Communications, PepQuery2 is a powerful tool that facilitates fast and targeted identification of both new and existing peptides in proteomics datasets obtained from mass spectrometry experiments. It...
July 10, 2023
The National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium (CPTAC) and the Switzerland International Cancer Proteogenome Consortium (ICPC) team at ETH Zürich are pleased to announce the formalization of an extension to their memorandum of understanding (MOU) for collaborative...
June 28, 2023
The limited availability of patient tissue samples poses a constant challenge for omics researchers, particularly in determining which analyses are feasible based on sample input requirements. Existing parallel workflows for multi-omic analyses have yielded valuable insights but are often restricted...
June 5, 2023
The United States National Cancer Institute (NCI) and Taiwan are pleased to announce the signing of an extension to their memoranda of understanding (MOUs) for proteogenomics cancer research with Academia Sinica and Chang Gung University. This extension marks a renewed commitment to the collaboration...